Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer

Lung Cancer(2021)

引用 9|浏览64
暂无评分
摘要
•MDT decision-making for stage III NSCLC was studied between 2015–2017.•Surgery or chemo-radiotherapy were recommended in just 61 % of patients.•Deaths from NSCLC at ≤2 years were seen in 41–43 % after all treatments.•Better tolerated and more effective treatments are needed in stage III NSCLC.
更多
查看译文
关键词
Non-small cell lung cancer,Stage III,Multidisciplinary tumor board,Predictors patterns of care,Treatment outcome
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要